News
App launches feature to address underserved women’s health conditions
Rosy aims to take its app beyond sexual wellness and into other underserved areas of women’s health, including endometriosis and fibroids
The US sexual wellness app Rosy has expanded its platform into other underserved areas of women’s health, including endometriosis, menopause and fibroids.
Rosy, a digital platform currently available in the US and Canada, aims to reduce the shame and stigma around women’s health and provide an “evidence-based”, multidisciplinary approach that supports women holistically.
The Dallas-based start-up launched in 2019 with an app that promotes sexual wellness for women by “bridging the gap” between what physicians can offer in their offices and what women need to thrive in their day-to-day lives.
Now, the company is expanding that mission by taking its platform beyond sexual wellness and into other underserved areas of women’s health, such as endometriosis, fibroids, menopause and migraines.
The development is hoped to establish Rosy as the first physician-founded platform that offers “lifetime support” for women.
“We don’t need support only when we go to the doctor; we have health concerns every day,” Rosy founder and CEO, Dr Lyndsey Harper, told Femtech World.
“We are Googling these concerns and looking them up on social media, but the challenge is that we don’t know what to trust. With Rosy, we’re trying to create that safe landing space that women can turn to if they have a question about their health.”
As part of the expansion, Rosy has debuted Quickies, a free feature that allows healthcare professionals to share educational content on the platform, called “quickies”, in a casual video format, similar to social media. All content is vetted by the company’s in-house medical team.
“Ten years ago, if someone was coming for a contraception visit, I used to present them with the options that they needed. Now, the dynamic of the visit has changed because of social media,” Harper said.
“Women come to us with lot of misinformation and that can be frustrating for physicians who have a limited amount of time to spend with patients.
“Through our healthcare provider community, we are aiming to empower physicians to spread the evidence-based education that they want their patients to have. If somebody learns something on Rosy, we know it’s at least going to be within the realm of evidence-based medicine.”
Harper launched Rosy with the aim to address an urgent need. While practicing as an OB/GYN, she saw hundreds of patients with sexual health concerns that weren’t being properly addressed.
“The reason why I decided to go into the start-up world and into sexual health particularly is because my patients were not getting the support they needed,” she explained.
“Unfortunately, as physicians, we have a very limited amount of time to spend with our patients and we need to do so much during a visit. I wanted to develop a resource for women that supports them holistically and helps them understand what is really going on with their bodies.”
With a total of US$5m in funding raised to date, the founder managed to build a platform that is now recommended by 11 per cent of OB/GYNs in the US.
“We’re really hoping to help women know that they don’t have to suffer in silence,” she said.
“For us, it’s really about helping women feel supported, connected and hopeful about their health.”
To receive the Femtech World newsletter, sign up here.
Entrepreneur
Future Fertility raises Series A financing to scale AI tools redefining fertility care worldwide
Future Fertility Inc. has announced the closing of a US$4.1 million Series A financing round.
The round was led by M Ventures (the corporate venture capital arm of Merck KGaA, Darmstadt, Germany) and Whitecap Venture Partners, with participation from new investors Sandpiper Ventures, Gaingels, and Jolt VC.
The financing will accelerate Future Fertility’s commercial expansion into Asia-Pacific and support its entry into the United States, including planned FDA 510(k) clearance for additional products as part of a broader U.S. market entry strategy.
Proceeds will also advance the development of a broader AI platform, from egg assessment through to embryo transfer, designed to support clinicians, embryologists, and patients across the full IVF journey.
M Ventures and Whitecap have supported Future Fertility’s mission to translate AI innovation into meaningful clinical outcomes since the company’s earliest stages.
Oliver Hardick, investment director, M Ventures, said: “Future Fertility is addressing a critical unmet need in reproductive medicine with a differentiated AI platform grounded in clinical data and real-world workflow integration.
“We are excited to continue supporting the company and team because we believe its technology has the potential to improve decision-making for clinicians, bring greater clarity to patients, and help advance a more personalised standard of care in fertility treatment.”
Future Fertility’s AI platform addresses a long-standing gap in fertility care: historically, there has been no objective, clinically validated method for assessing egg quality (Gardner et al., 2025), despite it being one of the most important drivers of reproductive success.
The company’s suite of deep learning tools includes VIOLET™, MAGENTA™, and ROSE™, purpose-built for egg freezing, IVF, and egg donation respectively.
The tools are based on AI models trained and validated on more than 650,000 oocyte images and are deployed in over 300 clinics across 35 countries.
Rhiannon Davies, founding and managing partner, Sandpiper Ventures, said: “The best outcomes in fertility care globally come from better data and smarter tools. Future Fertility understands that, and they’ve built a platform that delivers on it.
“Sandpiper is proud to back a team turning rigorous science into real results for patients and clinicians alike.”
Partnerships with the world’s leading fertility networks – including IVI RMA and Eugin Group across Latin America and Europe, FertGroup Medicina Reproductiva in Brazil, and most recently announced Kato Ladies Clinic in Japan – reflect growing demand for objective, AI-powered oocyte assessment in fertility care. In the United States, ROSE™ is newly available under an FDA 513(g) determination.
Research shows that approximately 50 per cent of IVF patients do not understand their likelihood of success, and many discontinue treatment prematurely, even though cumulative success rates improve significantly with multiple cycles (McMahon et al., 2024).
By delivering earlier clarity on egg quality, Future Fertility’s tools support more informed conversations between clinicians and patients, helping set realistic expectations and guide decisions about next steps.
Future Fertility’s growing evidence base spans seven peer-reviewed publications in Human Reproduction, Reproductive BioMedicine Online, Fertility & Sterility, and Nature’s Scientific Reports, and more than 70 scientific abstracts accepted and presented with partner clinics at conferences worldwide.
Christine Prada, CEO, Future Fertility, said: “Fertility treatment is one of the most emotionally and physically demanding experiences a person can go through.
“Every patient deserves objective data, not just a best guess, to support better decisions at critical moments in their care.
“This funding means we can bring that clarity to more patients, in more countries, at a moment when it matters most.”
Find out more about Future Fertility at futurefertility.com
Theramex has been censured over HRT failures that regulators said jeopardised patient safety.
The UK producer of HRT drugs, including Evorel and Intrarosa, was found to have breached fundamental compliance standards.
These included not updating crucial prescribing information, in some cases for several years, and not making clear that one drug must not be used during pregnancy.
The Prescription Medicines Code of Practice Authority issued the public reprimand after Theramex staff blew the whistle over what it described as “alarming” compliance issues and incomplete prescribing information for Evorel and Intrarosa that “jeopardise patient safety”.
Evorel patches, which contain estradiol, are among the most prescribed forms of transdermal HRT, meaning hormone treatment delivered through the skin. More than 250,000 items were issued in the last financial year, according to NHS Business Services Authority figures.
Overall, nearly 10m items of estradiol, including gels, were prescribed in the 2024/25 financial year.
The employees’ concerns included failing to provide comprehensive side-effect information in Evorel’s prescribing information, and not updating Intrarosa’s product information since 2019.
The PMCPA also reprimanded the company over failures to specify in advertising at a reproduction and advertising conference that Yselty, used to treat uterine fibroids, should not be taken during pregnancy.
In total, the PMCPA found Theramex had breached the Association of the British Pharmaceutical Industry’s code of practice 21 times.
The panel said the breaches not only jeopardised patient safety, but that Theramex had “brought discredit upon, and reduced confidence in, the pharmaceutical industry”.
The PMCPA also condemned Theramex’s decision to leave the regulator’s jurisdiction.
“By leaving the self-regulatory framework and requiring the Medicines and Healthcare products Regulatory Agency to assume full responsibility for regulating it, Theramex has inevitably delayed any regulatory action and oversight,” it said.
Dr Amit Aggarwal, medical director of the ABPI, said: “Theramex has fallen seriously short of the standards expected under our strict ABPI code of practice, and it’s right that the PMCPA took action.
“It’s also disappointing that as a result, the company has decided to leave the pharmaceutical industry’s self-regulatory system, which holds companies to standards above and beyond the law.”
Julian Beach, MHRA’s executive director of healthcare quality and access, said he was disappointed Theramex had left the PMCPA, but that the MHRA would take any necessary steps to ensure patient safety.
He said: “Leaving the jurisdiction of the PMCPA does not mean a company escapes scrutiny.
“The MHRA has legal powers to investigate and act on concerns about medicines that may impact public safety. Breaches of regulations can amount to criminal offences.”
A spokesperson for Theramex said: “Upholding ethical standards, compliance, and patient safety is very important to us. We acted promptly to address these historical matters as soon as we became aware of them.
“We take these matters seriously and have undertaken a comprehensive review of our compliance framework, including commissioning an independent external audit and implementing a broad programme of enhancements.
“As part of this process, we concluded it is most appropriate to be regulated with respect to UK medicines legislation by the MHRA, while continuing to uphold the spirit and principles of the EFPIA and ABPI codes of practice.
“Therefore, we withdrew from the PMCPA’s jurisdiction in January 2026. This approach allows us to focus our resources on maintaining high standards of ethical and compliant behaviour, with patient safety.”
Entrepreneur
Women’s HealthX confirms exceptional speaker line-up to advance fertility and reproductive care
By Women’s HealthX
Women’s HealthX has confirmed an outstanding cohort of fertility and reproductive care leaders for its upcoming event, bringing together the senior clinicians, medical directors, and innovators shaping evidence-based practice across hospitals and healthcare systems globally.
Timed to coincide with Infertility Awareness Week, this announcement underscores the event’s commitment to accelerating the adoption of evidence-based innovations in fertility and reproductive medicine.
Find out more about Women’s HealthX
Headline Speaker
Fireside Chat: The Invisible Disease: What Endometriosis Reveals About the Future of Women’s Health
Padma Lakshmi, Co-Founder, Endometriosis Foundation of America
Confirmed Speakers from World-Leading Institutions and confirmed sessions
Training the Next Generation of Fertility HCPs
Alan Penzias, Director, Fellowship Program in Reproductive Endocrinology & Infertility, Beth Israel Deaconess Medical Center
Shaping the Future of Fertility Care
Lynn Mason, Chief Executive Officer — North America, IVIRMA Global
Ovarian Aging and Reproductive Potential: What Truly Matters
Mark Trolice, Founder & Medical Director, The IVF Center
The Patient Journey Through Fertility Care: Improving Experience & Outcomes
Adam Balen, Chief Medical Officer / Professor of Reproductive Medicine, Leeds Teaching Hospitals NHS Trust
Designing Women’s Health Around The Whole Woman: A Life-Course Model for Sustainable Outcomes
Malissa Wood, Chief Medical Officer, Women as One
Prolong Fertility Preservation by Highlighting Ovarian Insufficiency Through Genetic Variant Data Analysis
Julie Rios, Division Director, Reproductive Endocrinology & Infertility, UPMC
What Attendees Will Take Away
How to improve the fertility patient journey and outcomes
- Ways to detect ovarian aging earlier using genetic insights
- Strategies to deliver care across the full female life course
- Approaches to training the next generation of fertility specialists
Women’s HealthX spans seven dedicated stages covering the full lifecycle of women’s health — from fertility and sexual health to maternity and menopause — providing attendees with actionable insights from frontline leaders across hospitals and healthcare systems.
With Chief Medical Officers and senior clinical leaders in attendance, the programme moves beyond discussion into delivery, giving attendees direct access to the latest clinical evidence, emerging digital tools, and real-world outcomes data to support integrated, high-quality care.
REGISTER NOW FOR A CHANCE TO WIN A FREE THERAPEUTIC MASSAGE
Complimentary passes are available for qualified healthcare professionals.
Attendees who register by 15 May will gain full access to all seven stages and a chance to receive a complimentary therapeutic massage at Encore Boston.
Register your complimentary place
For speaking opportunities, partnership enquiries, or further information, please contact the team directly at info@alpahevents.com
Entrepreneur3 weeks agoThree sessions that show exactly where women’s health is heading in 2026
Pregnancy3 weeks agoHow NIPT has evolved and what AI NIPT means in 2026
Menopause4 weeks agoWatchdog bans five ads for women’s heath claims
Entrepreneur4 weeks agoWHIS USA 2026 announces first ticket release for landmark Women’s Health Innovation Summit
News3 weeks agoTwo weeks left to make your mark in women’s cardiovascular health
Opinion3 weeks agoQ1 momentum: Female founders are advancing, but the system still hasn’t caught up
News4 weeks agoEndometriosis firm wins NIH prize
Pregnancy4 weeks agoMiscarriage cradle to be rolled out across Scotland